ArticlePloS one2009
GSK3beta is involved in JNK2-mediated beta-catenin inhibition.
Article in PloS one, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- AI-aided identification of dual-purpose therapeutic targets PRPF19 and MAPK9 in hepatocellular carcinoma and cellular senescence.npj aging · 2025Article
- The Role of the Dysregulated JNK Signaling Pathway in the Pathogenesis of Human Diseases and Its Potential Therapeutic Strategies: A Comprehensive Review.Biomolecules · 2024Review
- A Protective Role of Canonical Wnt/Mediators of inflammation · 2024Review
- An Update on the Effects of Probiotics on Gastrointestinal Cancers.Frontiers in pharmacology · 2021Review
- Modulation of JNK-1/ β-catenin signaling byRSC advances · 2019Article
- Perspectives on Wnt Signal Pathway in the Pathogenesis and Therapeutics of Chronic Obstructive Pulmonary Disease.The Journal of pharmacology and experimental therapeutics · 2019Review
- Cytoprotective Effect of Taurine against Hydrogen Peroxide-Induced Oxidative Stress in UMR-106 Cells through the Wnt/β-Catenin Signaling Pathway.Biomolecules & therapeutics · 2018Article
- Tetraspanin-2 promotes glucotoxic apoptosis by regulating the JNK/β-catenin signaling pathway in human pancreatic β cells.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2016Article
- Novel role of STRAP in progression and metastasis of colorectal cancer through Wnt/β-catenin signaling.Oncotarget · 2016Article
- 14-3-3 Binding and Sumoylation Concur to the Down-Modulation of β-catenin Antagonist chibby 1 in Chronic Myeloid Leukemia.PloS one · 2015Article
- Anticancer activities of sulindac in prostate cancer cells associated with c-Jun NH2-terminal kinase 1/β-catenin signaling.Oncology letters · 2014Article
- IKK-β/NF-κB p65 mediates p27(Kip1) protein degradation in arsenite response.Biochemical and biophysical research communications · 2014Article
- Selenium and sulindac are synergistic to inhibit intestinal tumorigenesis in Apc/p21 mice.Journal of hematology & oncology · 2013Article
- Effect of κ-opioid receptor agonist on the growth of non-small cell lung cancer (NSCLC) cells.British journal of cancer · 2012Article
- Characterization of the expression, promoter activity and molecular architecture of fibin.BMC biochemistry · 2011Article
- Genome-wide screen reveals WNT11, a non-canonical WNT gene, as a direct target of ETS transcription factor ERG.Oncogene · 2011Article
- Kinase activity profiling of pneumococcal pneumonia.PloS one · 2011Article
- Loss of JNK2 increases intestinal tumor susceptibility in Apc1638+/- mice with dietary modulation.Carcinogenesis · 2011Article
- Functional and physical interaction between the selenium-binding protein 1 (SBP1) and the glutathione peroxidase 1 selenoprotein.Carcinogenesis · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundWe have recently reported that mitogen-activated protein kinase (MAPK) JNK1 downregulates beta-catenin signaling and plays a critical role in regulating intestinal homeostasis and in suppressing tumor formation. This study was designed to determine whether JNK2, another MAPK, has similar and/or different functions in the regulation of beta-catenin signaling. METHODOLOGY AND PRINCIPAL
findingsWe used an in vitro system with manipulation of JNK2 and beta-catenin expression and found that activated JNK2 increased GSK3beta activity and inhibited beta-catenin expression and transcriptional activity. However, JNK2-mediated downregulation of beta-catenin was blocked by the proteasome inhibitor MG132 and GSK3beta inhibitor lithium chloride. Moreover, targeted mutations at GSK3beta phosphorylation sites (Ser33 and Ser37) of beta-catenin abrogated JNK2-mediated suppression of beta-catenin. In vivo studies further revealed that JNK2 deficiency led to upregulation of beta-catenin and increase of GSK3-beta phosphorylation in JNK2-/- mouse intestinal epithelial cells. Additionally, physical interaction and co-localization among JNK2, beta-catenin and GSK3beta were observed by immunoprecipitation, mammalian two-hybridization assay and confocal microscopy, respectively. CONCLUSION AND SIGNIFICANCE: In general, our data suggested that JNK2, like JNK1, interacts with and suppresses beta-catenin signaling in vitro and in vivo, in which GSK3beta plays a key role, although previous studies have shown distinct functions of JNK1 and JNK2. Our study also provides a novel insight into the crosstalk between Wnt/beta-catenin and MAPK JNKs signaling.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.